Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Bladder Cancer

Free Subscription 02.06.2025 2 Aktuelle Urol 2 Ann Surg Oncol 2 Anticancer Res 1 Arch Pathol Lab Med 1 Asia Pac J Clin Oncol 1 Asian Pac J Cancer Prev 1 Biology (Basel) 1 Biomed Pharmacother 2 Biomedicines 1 BJU Int 1 BJUI Compass 1 BMC Cancer 1 BMC Neurol 1 BMC Urol 2 BMJ Case Rep 1 Cancer Innov 1 Cancer Treat Res Commun 1 Cancers (Basel) 1 Cell Biol Toxicol 1 Chemotherapy 1 Clin Genitourin Cancer 1 Crit Rev Clin Lab Sci 1 Cureus 1 Curr Oncol 1 Dis Markers 3 Discov Oncol 1 Diseases 1 Eur Urol Focus 1 Expert Rev Anticancer Ther 3 Front Immunol 1 Gene 1 Hum Pathol 2 In Vitro Cell Dev Biol Anim 1 Int J Biol Macromol 2 Int J Mol Sci 1 J Drug Target 1 J Egypt Natl Canc Inst 1 J Immunother Cancer 1 J Robot Surg 1 Nat Cancer 1 Neoplasia 1 Nucleosides Nucleotides Nucleic Acids 1 Oncogene 2 Oncol Lett 1 Pharmaceuticals (Basel) 1 Pract Radiat Oncol 1 Rheumatology (Oxford) 4 Sci Rep 1 Toxicol In Vitro 4 Urol Oncol 2 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aktuelle Urol

1. NIENTIEDT M, Waldbillig F
   [Bimodal and multimodal endoscopy of the urinary bladder in diagnosis and treatment].
   Aktuelle Urol. 2025;56:242-247.
   PubMed         Abstract available
   
   
2. TUCHENHAGEN K, Vag T, Kriegmair MC
   [mpMRI of the Urinary Bladder: Significance and Clinical Use].
   Aktuelle Urol. 2025;56:248-257.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. LONGONI M, Marmiroli A, Falkenbach F, Le QC, et al
   Cancer-Specific Mortality of Partial Cystectomy Versus Radical Cystectomy in T2N0M0 Urothelial Bladder Cancer.
   Ann Surg Oncol. 2025 May 27. doi: 10.1245/s10434-025-17488.
   PubMed         Abstract available
   
   
4. ZHENG Q
   ASO Author Reflections: Artificial Intelligence in Bladder Cancer-Transforming Diagnosis and Treatment Paradigms.
   Ann Surg Oncol. 2025 May 28. doi: 10.1245/s10434-025-17538.
   PubMed        
   
   

   
   Anticancer Res

5. ONISHI T, Sekito S, Shibahara T, Yabana T, et al
   Randomized Study of Short-time Continuous Saline Irrigation After Transurethral Resection in Non-muscle Invasive Bladder Cancer.
   Anticancer Res. 2025;45:2653-2660.
   PubMed         Abstract available
   
   
6. MATSUO T, Miyata Y, Harada J, Itoh I, et al
   Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer.
   Anticancer Res. 2025;45:2563-2573.
   PubMed         Abstract available
   
   

   
   Arch Pathol Lab Med

7. WANG Y, Strzepek TJ, Costello DM, Crowley PA, et al
   Cytologic Assessment of the Supernatants of Formalin Solution Following Histologic Examination of Transurethral Biopsy/Resection Specimens: Potential Detection of Denuded Urothelial Cancer Cells.
   Arch Pathol Lab Med. 2025;149:573-577.
   PubMed         Abstract available
   
   

   
   Asia Pac J Clin Oncol

8. AIZEZI X, Silafu B, Ma Y, Wang Z, et al
   Analysis of IGFL2 Gene Expression and Prognostic Value in Bladder Cancer Based On TCGA Database.
   Asia Pac J Clin Oncol. 2025 May 29. doi: 10.1111/ajco.14191.
   PubMed         Abstract available
   
   

   
   Asian Pac J Cancer Prev

9. KASSEM A, Assem A, Sharawy A, Ezz El Deen M, et al
   The Effect of Surgeon Experience on the Recurrence of Non-Muscle Invasive Bladder Cancer (NMIBC), Following Transurethral Resection of the Bladder Tumor (TURBT): A double Blinded Prospective Randomized Study.
   Asian Pac J Cancer Prev. 2025;26:1767-1771.
   PubMed         Abstract available
   
   

   
   Biology (Basel)

10. YANG J, Wu W, Tang X
    Integration of Single-Cell and Bulk Transcriptome to Reveal an Endothelial Transition Signature Predicting Bladder Cancer Prognosis.
    Biology (Basel). 2025;14:486.
    PubMed         Abstract available
    
    

    
    Biomed Pharmacother

11. FURRIEL F, Ferreira H, Sampaio-Ribeiro G, Pereira M, et al
    Co-targeting the CD73-adenosinergic axis enhances the anti-tumor efficacy of anti-PD-L1 immunotherapy in bladder cancer.
    Biomed Pharmacother. 2025;188:118188.
    PubMed         Abstract available
    
    

    
    Biomedicines

12. LIU F, Li K, Zhu Q
    Targeting Metabolic Reprogramming in Bladder Cancer Immunotherapy: A Precision Medicine Approach.
    Biomedicines. 2025;13:1145.
    PubMed         Abstract available
    
    
13. ZHANG J, Jiang Z, Jin J, Kadeerhan G, et al
    Investigating the Genetic Links Between Immune Cell Profiles and Bladder Cancer: A Multidisciplinary Bioinformatics Approach.
    Biomedicines. 2025;13:1203.
    PubMed         Abstract available
    
    

    
    BJU Int

14. KWONG JCC, Pace K, Al-Daqqaq Z, Chelliahpillai Y, et al
    Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.
    BJU Int. 2025 May 26. doi: 10.1111/bju.16793.
    PubMed         Abstract available
    
    

    
    BJUI Compass

15. YAJIMA S, Imasato N, Masuda H
    Novel neoadjuvant therapies for muscle-invasive bladder cancer: Systematic review and meta-analysis.
    BJUI Compass. 2025;6:e70031.
    PubMed         Abstract available
    
    

    
    BMC Cancer

16. XU M, Zhou J, Lv J, Zhang Y, et al
    Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer analysis.
    BMC Cancer. 2025;25:932.
    PubMed         Abstract available
    
    

    
    BMC Neurol

17. WU F, Huang K, Yang J, Zhang L, et al
    Septicemia following sudden pituitary apoplexy after bladder tumor surgery: a case report.
    BMC Neurol. 2025;25:228.
    PubMed         Abstract available
    
    

    
    BMC Urol

18. YAPRAK BAYRAK B, Dogan HN, Teke K, Yuvak H, et al
    The role of tumor-infiltrating lymphocytes and depth of invasion in T1 bladder cancer: a retrospective analysis.
    BMC Urol. 2025;25:135.
    PubMed         Abstract available
    
    

    
    BMJ Case Rep

19. WONG BNX, Francis M, El-Khoury HJ, Woon D, et al
    Infrapubic Foley catheter balloon tamponade for retropubic venous haemorrhage during radical cystoprostatectomy and urethrectomy.
    BMJ Case Rep. 2025;18:e265030.
    PubMed         Abstract available
    
    
20. H B, Meshram N, Thomas T, C H H, et al
    Metanephrine normal, DOTATATE negative paraganglioma of the urinary bladder.
    BMJ Case Rep. 2025;18:e266048.
    PubMed         Abstract available
    
    

    
    Cancer Innov

21. LI N, Wang L, Yang Q, Li F, et al
    Identification and Evaluation of the Urinary Microbiota Associated With Bladder Cancer.
    Cancer Innov. 2025;4:e70012.
    PubMed         Abstract available
    
    

    
    Cancer Treat Res Commun

22. RICHTERS A, Suelmann B, Franken M, Mehra N, et al
    Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045.
    Cancer Treat Res Commun. 2025;43:100931.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

23. CAMPISTOL M, Lozano F, Carrion A, Raventos CX, et al
    Active Surveillance in Non-Muscle Invasive Bladder Cancer: A Systematic Review.
    Cancers (Basel). 2025;17:1714.
    PubMed         Abstract available
    
    

    
    Cell Biol Toxicol

24. GAO Y, Xu H, Zhao Q, Cai D, et al
    The key regulator circPDE3B promotes arsenic-induced bladder carcinogenesis by affecting STAT3 and NF-kappaB stability.
    Cell Biol Toxicol. 2025;41:91.
    PubMed         Abstract available
    
    

    
    Chemotherapy

25. HARANO T, Ikeda M, Hirano S, Shimura S, et al
    Safety and Efficacy of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Pegfilgrastim in Japanese Patients with Advanced or Metastatic Urothelial Carcinoma.
    Chemotherapy. 2025;70:85-91.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

26. SWAMINATHAN M, Holt SK, Gore JL, Nyame YA, et al
    Association Between Rheumatoid Arthritis, Frailty Status, and Mortality in Older Adults with Bladder Cancer.
    Clin Genitourin Cancer. 2025 Apr 30:102369. doi: 10.1016/j.clgc.2025.102369.
    PubMed         Abstract available
    
    

    
    Crit Rev Clin Lab Sci

27. SANGUEDOLCE F, Cormio A, Zanelli M, Palicelli A, et al
    Diagnostic workout of glandular malignant lesions of the bladder according to the 5th WHO classification.
    Crit Rev Clin Lab Sci. 2025;62:301-312.
    PubMed         Abstract available
    
    

    
    Cureus

28. AHMAD A, Ranjan N, Babelay G, Dheeraj K, et al
    A Prospective Assessment of the Vesical Imaging Reporting and Data System in the Diagnosis of Muscle-Invasive Bladder Cancer.
    Cureus. 2025;17:e83068.
    PubMed         Abstract available
    
    

    
    Curr Oncol

29. FAHEY CC, Clark-Garvey S, Porten S, Kamat AM, et al
    Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium.
    Curr Oncol. 2025;32:278.
    PubMed         Abstract available
    
    

    
    Dis Markers

30. MARKERS D
    RETRACTION: Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer.
    Dis Markers. 2025;2025:9803765.
    PubMed         Abstract available
    
    

    
    Discov Oncol

31. LI P, Yang X, Liu Q, Zhang H, et al
    Bladder cancer biomarker analysis and drugtarget prediction based on pyroptosis-related genes.
    Discov Oncol. 2025;16:924.
    PubMed         Abstract available
    
    
32. XU H, Li J, Peng S, Bai Y, et al
    From exposure to innovation: decoding aromatic amines' role in bladder cancer mechanisms.
    Discov Oncol. 2025;16:888.
    PubMed         Abstract available
    
    
33. DENG X, Zheng R, Tan X, Yao K, et al
    HER2 prognostic values in non-muscle-invasive bladder cancer: a step towards personalized treatment for BCG instillation.
    Discov Oncol. 2025;16:891.
    PubMed         Abstract available
    
    

    
    Diseases

34. SHUKLA CP, Jain NK, O'Donnell MA, Vachhani KV, et al
    Desmocollin-3 and Bladder Cancer.
    Diseases. 2025;13:131.
    PubMed         Abstract available
    
    

    
    Eur Urol Focus

35. SONPAVDE GP
    Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard.
    Eur Urol Focus. 2025 May 23:S2405-4569(25)00121.
    PubMed         Abstract available
    
    

    
    Expert Rev Anticancer Ther

36. MANOLITSIS I, Kapriniotis K, Katsimperis S, Angelopoulos P, et al
    The use of ctDNA for muscle-invasive bladder cancer before and after radical cystectomy.
    Expert Rev Anticancer Ther. 2025 May 26. doi: 10.1080/14737140.2025.2512036.
    PubMed         Abstract available
    
    

    
    Front Immunol

37. ZHANG P, Zhang H, Yu W, Fan D, et al
    A lactate-related tSNE signature defines prognostic subtypes of bladder cancer and reveals LINC01094-mediated VIM stabilization in metastasis and drug resistance.
    Front Immunol. 2025;16:1593523.
    PubMed         Abstract available
    
    
38. ZHANG F, Li S
    Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions.
    Front Immunol. 2025;16:1591191.
    PubMed         Abstract available
    
    
39. HU W, Liang J, Luo J, Fan J, et al
    Elevated platelet-to-lymphocyte ratio predicts poor clinical outcomes in non-muscle invasive bladder cancer: a systematic review and meta-analysis.
    Front Immunol. 2025;16:1578069.
    PubMed         Abstract available
    
    

    
    Gene

40. DENG P, Zhong C, He P, Liu Q, et al
    Uncovering citron kinase as a key biomarker for predicting outcomes and therapy efficacy in non-muscle-invasive bladder cancer.
    Gene. 2025 May 21:149590. doi: 10.1016/j.gene.2025.149590.
    PubMed         Abstract available
    
    

    
    Hum Pathol

41. KORENTZELOS D, Diamantopoulos L, Mohebnasab M, Dhir R, et al
    Plasmacytoid urothelial carcinoma of the urinary bladder: A single institution experience with focus on next-generation sequencing (NGS) and PD-L1 immunohistochemistry.
    Hum Pathol. 2025;158:105788.
    PubMed         Abstract available
    
    

    
    In Vitro Cell Dev Biol Anim

42. QIU Y, Ruan H, Ji D, Cao N, et al
    NEURL1 acts as a candidate suppressor in bladder cancer by down-regulating PDE9A.
    In Vitro Cell Dev Biol Anim. 2025 May 29. doi: 10.1007/s11626-025-01047.
    PubMed         Abstract available
    
    
43. LIU Z, Chen Z, Yang H, Liu J, et al
    miR-944 inhibits malignant progression of bladder cancer through ATIC/AKT/FOXO3 A axis mediated by SHMT1.
    In Vitro Cell Dev Biol Anim. 2025 May 29. doi: 10.1007/s11626-025-01050.
    PubMed         Abstract available
    
    

    
    Int J Biol Macromol

44. QIN J, Liao K, Huang L, Qiu R, et al
    Proteome-driven transcriptomic dissection of EMT networks in bladder cancer based on the VIM and CDH2 protein macromolecules influence: From molecular-protein subtyping to therapeutic target prioritization.
    Int J Biol Macromol. 2025;315.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

45. RELVAS-SANTOS M, Ferreira D, Brandao A, Afonso LP, et al
    Glycomics and Glycoproteomics Reveal Distinct Oligomannose Carriers Across Bladder Cancer Stages.
    Int J Mol Sci. 2025;26:4891.
    PubMed         Abstract available
    
    
46. STURM S, Niegisch G, Windolf J, Suschek CV, et al
    Correction: Sturm et al. Exposure of Bladder Cancer Cells to Blue Light (lambda = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine. Int. J. Mol. Sci. 2024, 25, 4868.
    Int J Mol Sci. 2025;26:4790.
    PubMed         Abstract available
    
    

    
    J Drug Target

47. SHI Q, Geng J, Han L, Ji X, et al
    Engineered Salmonella Carrying siRNA-PD-1 Shrinks orthotopically implanted Bladder Cancer in Rats.
    J Drug Target. 2025 May 26:1-12. doi: 10.1080/1061186X.2025.2512619.
    PubMed         Abstract available
    
    

    
    J Egypt Natl Canc Inst

48. BDIOUI A, Akkari M, Krifa M, Souiden Y, et al
    Microsatellite instability and mismatch repair deficiency in bladder urothelial carcinoma: a Tunisian single-center study.
    J Egypt Natl Canc Inst. 2025;37:22.
    PubMed         Abstract available
    
    

    
    J Immunother Cancer

49. BLANC J, Carnot A, Barthelemy P, Casert V, et al
    Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.
    J Immunother Cancer. 2025;13:e012045.
    PubMed         Abstract available
    
    

    
    J Robot Surg

50. LIU QF, Hao P, Wang T
    A meta-analytic appraisal of robotic-assisted cystectomy outcomes in the elderly octogenarian population.
    J Robot Surg. 2025;19:232.
    PubMed         Abstract available
    
    

    
    Nat Cancer

51. DANELLI L
    Sex-specific gut microbiota and neutrophil senescence in bladder cancer.
    Nat Cancer. 2025;6:738.
    PubMed        
    
    

    
    Neoplasia

52. HASSOUNEH Z, Noel ODV, Ji N, Kim ME, et al
    CD56 on intratumoral NK cells: orchestrating NK cell-mediated anti-tumor effects in bladder cancer.
    Neoplasia. 2025;66:101187.
    PubMed         Abstract available
    
    

    
    Nucleosides Nucleotides Nucleic Acids

53. ZHANG J, Yang H, Zhang X, Chen J, et al
    Prognostic significance of copper metabolism-related genes as risk markers in bladder urothelial carcinoma.
    Nucleosides Nucleotides Nucleic Acids. 2025;44:598-616.
    PubMed         Abstract available
    
    

    
    Oncogene

54. WEI X, Wang B, Yang Y, Fang Z, et al
    Crosstalk between SUMOylation and ubiquitination controls the stability of transcription factor zinc finger protein 24: a novel antitumor mechanism in bladder cancer.
    Oncogene. 2025 May 28. doi: 10.1038/s41388-025-03450.
    PubMed         Abstract available
    
    

    
    Oncol Lett

55. ADAN MM, Mao X, Ding L, Abdullahi KM, et al
    Efficacy and safety of BCG and immune checkpoint inhibitors in non-muscle invasive bladder cancer: A meta-analysis with exploratory chemotherapy comparisons.
    Oncol Lett. 2025;30:348.
    PubMed         Abstract available
    
    
56. YAMAMOTO A, Izutsu R, Seong H, Shimizu R, et al
    AMIGO2 expression at the invasive front of bladder cancer predicts recurrence-free and overall survival after radical cystectomy.
    Oncol Lett. 2025;30:339.
    PubMed         Abstract available
    
    

    
    Pharmaceuticals (Basel)

57. BERTAUX M, Luo C, Radulescu C, Beuzeboc P, et al
    Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients.
    Pharmaceuticals (Basel). 2025;18:701.
    PubMed         Abstract available
    
    

    
    Pract Radiat Oncol

58. ACHARD V, Abdel-Aty H, Santana VD, Bebek M, et al
    Combining Radiotherapy with Immune Checkpoint Inhibitors for the Management of Muscle-Invasive Bladder Cancer: A Comprehensive Systematic Review from the Y-ECI ROSC EORTC group.
    Pract Radiat Oncol. 2025 May 22:S1879-8500(25)00147.
    PubMed         Abstract available
    
    

    
    Rheumatology (Oxford)

59. LEE D, Jeon KH, Jung J, Han K, et al
    Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study.
    Rheumatology (Oxford). 2025;64:3458-3467.
    PubMed         Abstract available
    
    

    
    Sci Rep

60. SHARMA P, Sharma B, Yadav DP, Thakral D, et al
    Bladder lesion detection using EfficientNet and hybrid attention transformer through attention transformation.
    Sci Rep. 2025;15:18042.
    PubMed         Abstract available
    
    
61. LI N, Wang X, Duan F, Wang X, et al
    Association of different treatment modalities for rectal cancer and second primary urinary system neoplasms, findings from SEER.
    Sci Rep. 2025;15:18782.
    PubMed         Abstract available
    
    
62. HUANG S, Jia K, Cui J, Duan J, et al
    Impact of pelvic lymph node dissection on survival outcomes in non-muscle invasive bladder cancer: a multicenter retrospective study.
    Sci Rep. 2025;15:18905.
    PubMed         Abstract available
    
    
63. HUANG H, Shao H, Wang Y, Ge L, et al
    Disulfide bond-related gene signature development for bladder cancer prognosis prediction and immune microenvironment characterization.
    Sci Rep. 2025;15:18826.
    PubMed         Abstract available
    
    

    
    Toxicol In Vitro

64. SAINI D, Chaudhary PK, Verma GK, Chaudhary JK, et al
    Molecular mechanistic approach to reveal decitabine's effect on DNMT gene modulation and its inhibitory role in heavy metal-induced proliferation in urinary bladder cancer cell line.
    Toxicol In Vitro. 2025 May 23:106082. doi: 10.1016/j.tiv.2025.106082.
    PubMed         Abstract available
    
    

    
    Urol Oncol

65. GERSHMAN B, Ernandez J, Kaul S, Perez-Londono A, et al
    Associations of a claims-based frailty index with perioperative outcomes and survival among older adults undergoing radical cystectomy for bladder cancer.
    Urol Oncol. 2025 May 27:S1078-1439(25)00168.
    PubMed         Abstract available
    
    
66. ZHU A, Sher J, Li R, Ioseliani O, et al
    What motivates bladder cancer patients to be active? A qualitative study assessing attitudes towards physical activity and digital health technologies.
    Urol Oncol. 2025 May 28:S1078-1439(25)00176.
    PubMed         Abstract available
    
    
67. ESCANO MRJ, Vertosick EA, D'Souza N, Benfante N, et al
    Re-analysis of intravesical gemcitabine in the era of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer.
    Urol Oncol. 2025 May 24:S1078-1439(25)00134.
    PubMed         Abstract available
    
    
68. KAYAR K, Kayar R, Karabay E, Ozdemir BB, et al
    Prognostic role of pathological substaging in high-grade pT1 bladder cancer undergoing BCG therapy: Insights on recurrence and progression.
    Urol Oncol. 2025 May 23:S1078-1439(25)00174.
    PubMed         Abstract available
    
    

    
    World J Urol

69. TISSOT G, Gabriel PE, Dubuet U, Regnier S, et al
    Impact on oncological outcomes of detrusor muscle absence in pTaHG urothelial carcinoma of the bladder? The end of the "jump" of the lamina propria layer myth.
    World J Urol. 2025;43:324.
    PubMed         Abstract available
    
    
70. SAVIN Z, Ben-David R, Durbhakula V, Gupta K, et al
    Does having an asymptomatic renal stone increase morbidity after radical cystectomy?
    World J Urol. 2025;43:336.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.